De Novo Human Leukocyte Antigen Allosensitization in Heartmate 3 Versus Heartmate II Left Ventricular Assist Device Recipients.
Journal
ASAIO journal (American Society for Artificial Internal Organs : 1992)
ISSN: 1538-943X
Titre abrégé: ASAIO J
Pays: United States
ID NLM: 9204109
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
pubmed:
23
4
2021
medline:
2
2
2022
entrez:
22
4
2021
Statut:
ppublish
Résumé
Left ventricular assist devices (LVADs) are associated with the development of antihuman leukocyte antigen (HLA) antibodies, which can create a challenge for future transplantation in these patients. The differential effects of Heartmate 3 (HM3) versus Heartmate II (HMII) on de novo HLA allosensitization remain unknown. Patients who underwent HMII or HM3 implantation and had no prior HLA antibodies by solid-phase assay (Luminex) testing were included in this study. Complement-dependent cytotoxicity (CDC) panel reactive antibody (PRA) levels and Luminex antibody profiles were followed until cardiac transplantation, device explantation, or death. Electronic medical records were reviewed to examine posttransplant outcomes. Thirty-eight HM3 and 34 HMII patients with complete data were followed for 1.5 ± 1.1 years on device support. HM3 and HMII groups had similar age at implant, female gender, ischemic heart failure etiology, bridge strategy at implant, as well as intraoperative and postoperative transfusion requirements. 39.5% of HM3 and 47.1% of HMII patients developed detectable HLA antibodies by Luminex testing (p = 0.516). Development of high-level (mean fluorescence intensity >10,000) antibodies was significantly lower in HM3 than HMII patients (5.3 vs. 20.6%, p = 0.049). CDC PRA testing showed fewer HM3 patients with a positive result (PRA > 0%) than HMII patients (39.4 vs. 70.0%, p = 0.015). Among transplanted patients, those who had developed de novo sensitization on LVAD support showed a trend toward incidence of moderate to severe grade rejection compared with unsensitized patients (23.8 vs. 4.8%, p = 0.078). HM3 is associated with lower risk of de novo HLA sensitization compared with HMII.
Identifiants
pubmed: 33883507
doi: 10.1097/MAT.0000000000001451
pii: 00002480-202202000-00014
doi:
Substances chimiques
HLA Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-232Informations de copyright
Copyright © ASAIO 2021.
Références
Kamdar F, John R, Eckman P, Colvin-Adams M, Shumway SJ, Liao K: Postcardiac transplant survival in the current era in patients receiving continuous-flow left ventricular assist devices. J Thorac Cardiovasc Surg 2013.145: 575–581
Slaughter MS, Rogers JG, Milano CA, et al.; HeartMate II Investigators: Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009.361: 2241–2251
Khush KK, Cherikh WS, Chambers DC, et al.: The international thoracic organ transplant registry of the international society for heart and lung transplantation: Thirty-sixth adult heart transplantation report—2019; focus theme: Donor and recipient size match. J Heart Lung Transpl 2019.38: 1056–66
Askar M, Hsich E, Reville P, et al.: HLA and MICA allosensitization patterns among patients supported by ventricular assist devices. J Heart Lung Transplant 2013.32: 1241–1248
Ko BS, Drakos S, Kfoury AG, et al.; Utah Transplant Affiliated Hospitals (U.T.A.H.) Cardiac Transplant Program: Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant. J Heart Lung Transplant 2016.35: 1024–1030
Mehra MR, Uriel N, Naka Y, et al.: A fully magnetically levitated left ventricular assist device—Final report. N Engl J Med 2019.380: 1618–27
Moazami N, Itescu S, Williams MR, Argenziano M, Weinberg A, Oz MC: Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant 1998.17: 876–880
Mehra MR, Uriel N, Naka Y, et al.; MOMENTUM 3 Investigators: A fully magnetically levitated left ventricular assist device—Final report. N Engl J Med 2019.380: 1618–1627
George I, Colley P, Russo MJ, et al.: Association of device surface and biomaterials with immunologic sensitization after mechanical support. J Thorac Cardiovasc Surg 2008.135: 1372–1379
Drakos SG, Kfoury AG, Kotter JR, et al.: Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. J Heart Lung Transplant 2009.28: 838–842
Itescu S, John R: Interactions between the recipient immune system and the left ventricular assist device surface: Immunological and clinical implications. Ann Thorac Surg 2003.75(Suppl 6): S58–S65
Schuster M, Kocher A, John R, et al.: B-cell activation and allosensitization after left ventricular assist device implantation is due to T-cell activation and CD40 ligand expression. Hum Immunol 2002.63: 211–220
Bourque K, Cotter C, Dague C, et al.: Design rationale and preclinical evaluation of the HeartMate 3 left ventricular assist system for hemocompatibility. ASAIO J 2016.62: 375–383
Elkind J, Sobczyk J, Ostberg-Braun O, Silva Enciso J, Adler E, Morris GP: Factors influencing transfusion-associated HLA sensitization in patients bridged to heart transplantation using ventricular assist device. Clin Transplant 2020.34: e13772
Kidambi S, Mohamedali B, Bhat G: Clinical outcomes in sensitized heart transplant patients bridged with ventricular assist devices. Clin Transplant 2015.29: 499–505
Chiu P, Schaffer JM, Oyer PE, et al.: Influence of durable mechanical circulatory support and allosensitization on mortality after heart transplantation. J Heart Lung Transplant 2016.35: 731–742
See SB, Clerkin KJ, Kennel PJ, et al.: Ventricular assist device elicits serum natural IgG that correlates with the development of primary graft dysfunction following heart transplantation. J Heart Lung Transplant 2017.36: 862–870
Bejar D, Colombo PC, Jennings D, et al.: Alloantibody desensitization therapy in bridge-to-transplant patients on continuous-flow left ventricular assist device support. J Heart Lung Transpl 2016.35: S282–S3
Cole RM, Kobashigawa JA: Desensitization strategies Pre- and post-cardiac transplantation. Curr Treat Options Cardiovasc Med 2016.18: 8
Kobashigawa JA, Patel JK, Kittleson MM, et al.: The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin Transplant 2011.25: E61–E67
Habal MV, Farr M, Restaino S, Chong A: Desensitization in the era of precision medicine: Moving from the bench to bedside. Transplantation 2019.103: 1574–1581
Massad MG, Cook DJ, Schmitt SK, et al.: Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 1997.64: 1120–1125